Filing Flows › BioNexus Gene Lab (BGLC) › Q2 2026 › vs Q1 2026
BioNexus Gene Lab (BGLC) Q2 2026 vs Q1 2026 (quarter over quarter)
BioNexus Gene Lab's revenue rose $53K (+233%) from $23K in Q1 2026 to $76K in Q2 2026.
BioNexus Gene Lab, Q2 2026: revenue $76K (-97% year over year), operating margin -370.8%, net loss $286K, operating cash flow −$422K. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $76K | $23K | $53K | +233% |
| Net loss | $286K | $544K | −$257K | -47% |
| Costs & expenses | $363K | $566K | −$204K | -36% |
| Operating costs | $359K | $563K | −$205K | -36% |
| Interest & other, net | $4K | $3K | $1K | +31% |
| Cost of revenue | $63K | $24K | $40K | +167% |
| Operating cash sources | $451K | $176K | $275K | +156% |
| Depreciation | $28K | $28K | −$228 | -0.8% |
| Cash used in operations | $422K | $148K | $275K | +186% |
| Net loss absorbed | $286K | $544K | −$257K | -47% |
| Working capital & other | $164K | −$368K | $532K | — |
Questions
How much did BioNexus Gene Lab's revenue grow quarter over quarter in Q2 2026?
BioNexus Gene Lab's revenue rose $53K (+233%) from $23K in Q1 2026 to $76K in Q2 2026.